T1EV34 Stock Overview
Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for T1EV34 from our risk checks.
Teva Pharmaceutical Industries Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$47.20 |
| 52 Week High | US$54.40 |
| 52 Week Low | US$23.97 |
| Beta | 0.87 |
| 11 Month Change | -8.88% |
| 3 Month Change | -6.72% |
| 1 Year Change | 121.18% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 110.34% |
Recent News & Updates
Recent updates
Shareholder Returns
| T1EV34 | BR Pharmaceuticals | BR Market | |
|---|---|---|---|
| 7D | -4.7% | -0.3% | 0.3% |
| 1Y | 121.2% | -18.8% | -1.7% |
Return vs Industry: T1EV34 exceeded the BR Pharmaceuticals industry which returned -18.8% over the past year.
Return vs Market: T1EV34 exceeded the BR Market which returned -1.7% over the past year.
Price Volatility
| T1EV34 volatility | |
|---|---|
| T1EV34 Average Weekly Movement | 5.8% |
| Pharmaceuticals Industry Average Movement | 6.7% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in BR Market | 8.3% |
| 10% least volatile stocks in BR Market | 2.2% |
Stable Share Price: T1EV34 has not had significant price volatility in the past 3 months compared to the BR market.
Volatility Over Time: T1EV34's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1901 | 37,000 | Richard Francis | www.tevapharm.com |
Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas.
Teva Pharmaceutical Industries Limited Fundamentals Summary
| T1EV34 fundamental statistics | |
|---|---|
| Market cap | R$111.40b |
| Earnings (TTM) | -R$5.54b |
| Revenue (TTM) | R$96.83b |
1.2x
P/S Ratio-20.1x
P/E RatioIs T1EV34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| T1EV34 income statement (TTM) | |
|---|---|
| Revenue | US$16.77b |
| Cost of Revenue | US$8.41b |
| Gross Profit | US$8.36b |
| Other Expenses | US$9.32b |
| Earnings | -US$959.00m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.85 |
| Gross Margin | 49.84% |
| Net Profit Margin | -5.72% |
| Debt/Equity Ratio | 297.3% |
How did T1EV34 perform over the long term?
See historical performance and comparison